{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:53:11Z","timestamp":1777679591566,"version":"3.51.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.7759\/cureus.105306","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:49:48Z","timestamp":1773665388000},"source":"Crossref","is-referenced-by-count":1,"title":["Levetiracetam and Rhabdomyolysis: A Rare but Clinically Significant Adverse Effect"],"prefix":"10.7759","author":[{"given":"Pricilla A","family":"Ababio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Wireko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mekdem","family":"Bisrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Deonarine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan","family":"Elkomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Azinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch BA","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004, 101:9861-9866. 10.1073\/pnas.0308208101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos PN","year":"2000","unstructured":"Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000, 85:77-85. 10.1016\/s0163-7258(99)00052-2","journal-title":"Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino JJ","year":"2000","unstructured":"Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000, 55:236-242. 10.1212\/wnl.55.2.236","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil B","year":"2008","unstructured":"Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008, 4:507-523. 10.2147\/ndt.s2937","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.05.005","article-title":"Rhabdomyolysis: review of the literature","volume":"24","author":"Zutt R","year":"2014","unstructured":"Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord. 2014, 24:651-659. 10.1016\/j.nmd.2014.05.005","journal-title":"Neuromuscul Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7369-9","article-title":"Postictal serum creatine kinase for the differential diagnosis of epileptic seizures and psychogenic non-epileptic seizures: a systematic review","volume":"262","author":"Brigo F","year":"2015","unstructured":"Brigo F, Igwe SC, Erro R, et al.. Postictal serum creatine kinase for the differential diagnosis of epileptic seizures and psychogenic non-epileptic seizures: a systematic review. J Neurol. 2015, 262:251-257. 10.1007\/s00415-014-7369-9","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2705","article-title":"Rhabdomyolysis: a rare adverse effect of levetiracetam","volume":"10","author":"Rastogi V","year":"2018","unstructured":"Rastogi V, Singh D, Kaur B, Arora P, Gadikota JP. Rhabdomyolysis: a rare adverse effect of levetiracetam. Cureus. 2018, 10:e2705. 10.7759\/cureus.2705","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch X","year":"2009","unstructured":"Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009, 361:62-72. 10.1056\/NEJMra0801327","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/467231-levetiracetam-and-rhabdomyolysis-a-rare-but-clinically-significant-adverse-effect","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:49:48Z","timestamp":1773665388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/467231-levetiracetam-and-rhabdomyolysis-a-rare-but-clinically-significant-adverse-effect"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.105306","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}